Elan/Biogen Idec Antegren Multiple Sclerosis Filing Slated For Mid-Year
BLA filing decision announced after a meeting with FDA to discuss first year of data from Phase III studies on use of natalizumab as monotherapy and in combination.
BLA filing decision announced after a meeting with FDA to discuss first year of data from Phase III studies on use of natalizumab as monotherapy and in combination.